News
SLS
3.860
+15.57%
0.520
Maxim Group Remains a Buy on SELLAS Life Sciences Group (SLS)
TipRanks · 2d ago
SELLAS Life Sciences Highlights Data From Early Study In Blood Cancer Patients
Benzinga · 12/13/2022 19:49
BRIEF-SELLAS Announces Positive Phase 1 Data With CDK9 Inhibitor GFH009 Monotherapy In Patients With Relapsed Hematologic Malignancies
Reuters · 12/13/2022 13:45
SELLAS Announces Phase 1 Data With CDK9 Inhibitor GFH009 Monotherapy In Patients With Relapsed/Refractory Hematologic Malignancies
Benzinga · 12/13/2022 13:31
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 12/08/2022 21:32
BRIEF-Sellas Life Sciences' Committee Recommends Galinpepimut-S Regal Trial To Continue As Planned
Reuters · 12/08/2022 15:47
Looking Into SELLAS Life Sciences Gr's Recent Short Interest
Benzinga · 12/08/2022 15:18
SELLAS Life Sciences Says Independent Committee Recommends Galinpepimut-S Trial to Proceed; Shares Rise
SELLAS Life Sciences Says Independent Committee Recommends Galinpepimut-S Trial to Proceed; Shares Rise
MT Newswires · 12/08/2022 13:50
SELLAS Life Sciences' Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial To Continue As Planned
Benzinga · 12/08/2022 13:33
SELLAS Life Sciences' CDK9 Inhibitor GFH009 Selected For Pediatric Preclinical In Vivo Testing Program In Pediatric Cancers By The National Cancer Institute
Benzinga · 12/06/2022 13:36
SELLAS Life Sciences' CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition In Small Cell Lung Cancer Murine Model
Benzinga · 12/01/2022 13:33
SELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summit
NEW YORK, Nov. 30, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, t...
GlobeNewswire · 11/30/2022 13:30
SELLAS Life Sciences Group Third Quarter 2022 Earnings: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021)
SELLAS Life Sciences Group ( NASDAQ:SLS ) Third Quarter 2022 Results Key Financial Results Net loss: US$7.02m (flat on...
Simply Wall St. · 11/16/2022 10:28
Alliance Global Partners Maintains Buy on SELLAS Life Sciences Gr, Lowers Price Target to $8
Benzinga · 11/15/2022 13:08
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/15/2022 10:19
Dow Surges 150 Points; Crude Oil Falls Sharply
Benzinga · 11/14/2022 19:34
SELLAS Life Sciences Shares Tumble As Acute Myeloid Leukemia Trial Will Longer Than Anticipated
Benzinga · 11/14/2022 18:25
BRIEF-Sellas Life Sciences Provides Business Update And Reports Q3 Financial Results
Reuters · 11/14/2022 18:20
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Benzinga · 11/14/2022 18:05
MMAT, PRCH and CABA among mid-day movers
Seekingalpha · 11/14/2022 17:51
More
Webull provides a variety of real-time SLS stock news. You can receive the latest news about Sellas Life Sciences Group Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLS
SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer immunotherapeutics for a range of cancer indications. The Company's product candidates include galinpepimut-S (GPS) and nelipepimut-S (NPS). Its lead product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK) that targets the Wilms tumor 1 (WT1) protein, which is present in 20 or more cancer types. GPS has potential both as a monotherapy and in combination to address a range of hematologic malignancies and solid tumor indications. Its second product candidate, NPS, is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 (HER2), which is expressing cancers with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, which includes triple negative breast cancer (TNBC) patients.